The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells

Pharmaceutical Biology

Volumn 51, Issue 4, 2013, Pages 447-454

  Shen, Fei Hai ^a   Jin, Jing ^a   Li, Jia ^a   Wang, Yan ^a   Zhu, Shao Hua ^a   Lu, Yu Jing ^a   Ou, Tian Miao ^a   Huang, Zhi Shu ^a   Huang, Min ^a   Huang, Zhi Ying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 N Methyl quindoline derivatives; Cell apoptosis; ERK phosphorylation; MEK

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N' (7 FLUORO 5 N METHYL 10H INDOLO[3,2 B]QUINOLIN 5 IUM) N,N DIMETHYLPROPANE 1,3 DIAMINE IODIDE; PROTEIN BAX; PROTEIN BCL 2; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; IC 50; IN VITRO STUDY; LEUKEMIA CELL; ONCOGENE C KIT; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZAMIDES; BLOTTING, WESTERN; CELL SURVIVAL; DIAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; G-QUADRUPLEXES; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; K562 CELLS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; QUINOLINES; QUINOLINIUM COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 84875193807     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2012.738424     Document Type: Article

References (31)

1. Al-Obeidi FA, Lam KS. (2000). Development of inhibitors for protein tyrosine kinases. Oncogene, 19, 5690-5701.
2. Beppu K, Jaboine J, Merchant MS, Mackall CL, Tiele CJ. (2004). Efect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst, 96, 46-55.
3. Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, Garofalo AW, Phuan PW, Fort DM, Litvak J, Gerber RE, Sloan B, Luo J, Cooper R, Reaven GM. (1998). Antihyperglycemic activities of cryptolepine analogues: An ethnobotanical lead structure isolated from Cryptolepis sanguinolenta. J Med Chem, 41, 2754-2764.
4. Chu S, Holtz M, Gupta M, Bhatia R. (2004). BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood, 103, 3167-3174.
5. Crews CM, Alessandrini A, Erikson RL. (1992). The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science, 258, 478-480.
6. Dolci S, Pellegrini M, Di Agostino S, Geremia R, Rossi P. (2001). Signaling through extracellular signal-regulated kinase is required for spermatogonial proliferative response to stem cell factor. J Biol Chem, 276, 40225-40233.
7. Domen J, Weissman IL. (2000). Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. J Exp Med, 192, 1707-1718.
8. Fernando H, Reszka AP, Huppert J, Ladame S, Rankin S, Venkitaraman AR, Neidle S, Balasubramanian S. (2006). A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry, 45, 7854-7860.
9. Ferrari S, Grande A, Zucchini P, Manfredini R, Tagliafco E, Rossi E, Temperani P, Torelli G, Emilia G, Torelli U. (1993). Overexpression of c-kit in a leukemic cell population carrying a trisomy 4 and its relationship with the proliferative capacity. Leuk Lymphoma, 9, 495-501.
10. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. (2002). Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ter, 1, 1115-1124.
11. Gounder MM, Maki RG. (2011). Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol, 67, 25-43.
12. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. (2004). Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA, 101, 15313-15317.
13. Holt SJ, Petrow V. (1947). Cabarzole, carbolines, and related compounds [Part 1. Quindoline Derivatives]. J Chem Soc, 18, 607-611.
14. Jalal Hosseinimehr S, Inanami O, Hamasu T, Takahashi M, Kashiwakura I, Asanuma T, Kuwabara M. (2004). Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res, 45, 557-561.
15. Kee D, Zalcberg Jr. (2012). Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ter Adv Med Oncol, 4, 255-270.
16. Krystal GW, Honsawek S, Litz J, Buchdunger E. (2000). The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res, 6, 3319-3326.
17. Lasater EA, Bessler WK, Mead LE, Horn WE, Clapp DW, Conway SJ, Ingram DA, Li F. (2008). Nf1+/-mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum Mol Genet, 17, 2336-2344.
18. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. (2005). Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells, 23, 16-43.
19. Lu YJ, Ou TM, Tan JH, Hou JQ, Shao WY, Peng D, Sun N, Wang XD, Wu WB, Bu XZ, Huang ZS, Ma DL, Wong KY, Gu LQ. (2008). 5-N-Methylated quindoline derivatives as telomeric g-quadruplex stabilizing ligands: efects of 5-N positive charge on quadruplex binding afnity and cell proliferation. J Med Chem, 51, 6381-6392.
20. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, Bonati A. (2003). Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia, 17, 1783-1793.
21. Orelio C, Dzierzak E. (2007). Bcl-2 expression and apoptosis in the regulation of hematopoietic stem cells. Leuk Lymphoma, 48, 16-24.
22. Ou TM, Lu YJ, Zhang C, Huang ZS, Wang XD, Tan JH, Chen Y, Ma DL, Wong KY, Tang JC, Chan AS, Gu LQ. (2007). Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem, 50, 1465-1474.
23. Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O'connor R, Wu YV, Motwani M, Chen JH, Schwartz GK, Singer S. (2006). Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res, 66, 5858-5866.
24. Scholl C, Gilliland DG, Fröhling S. (2008). Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol, 35, 336-345.
25. Todd AK, Haider SM, Parkinson GN, Neidle S. (2007). Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. Nucleic Acids Res, 35, 5799-5808.
26. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Grifn JD, Johnson BE, Salgia R. (2000). Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene, 19, 3521-3528.
27. Wang XD, Ou TM, Lu YJ, Li Z, Xu Z, Xi C, Tan JH, Huang SL, An LK, Li D, Gu LQ, Huang ZS. (2010). Turning of transcription of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with quindoline derivatives. J Med Chem, 53, 4390-4398.
28. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. (2005). AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA, 102, 1104-1109.
29. Yang SW, Abdel-Kader M, Malone S, Werkhoven MC, Wisse JH, Bursuker I, Neddermann K, Fairchild C, Raventos-Suarez C, Menendez AT, Lane K, Kingston DG. (1999). Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest. J Nat Prod, 62, 976-983.
30. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. (1987). Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentifed ligand. EMBO J, 6, 3341-3351.
31. + human myeloid leukemia cells. Cancer Res, 63, 2118-2126.